Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RQ3013 in Healthy Adults
NCT05394012Phase 1Unknown
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 1, randomised, double-blind trial of RQ3013 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Walvax Biotechnology Co., Ltd. Primary endpoints: Immediate adverse events, Solicited local and systemic adverse events and 1 more. Status: unknown.
02
Drugs
RQ3013
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05394012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394012.